Clinical trials: Pediatric Attention Deficit Hyperactivity Disorder
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Attention Deficit Hyperactivity Disorder
The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
This study was designed to compare Concerta Extended Release tablets with Metadate CD capsules in children with ADHD who were between 6 and 12 years old.
- Trial name
- NCT00381758
- Testing
- Methylphenidate Extended Release Capsules
- Volunteers
- 184 people
- Sponsor
- UCB Pharma
ADHD
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this study is to assess the time of onset of Vyvanse compared to placebo, in the analog classroom as measured by the Swanson, Kotkin, Agler, M.
- Trial name
- NCT00500149
- Testing
- Vyvanse (lisdexamfetamine dimesylate)
- Where
- 9 sites in United States
- Volunteers
- 129 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
Software Treatment for Actively Reducing Severity of ADHD - Follow Up
This is an exploratory study to assess potential maintenance of clinical benefit (cognition and symptoms) following 4 weeks of at-home digital therapy in ADHD children.
- Trial name
- STARS-ADHD2 (NCT02828644)
- Testing
- EVO
- Where
- 15 sites in United States
- Volunteers
- 175 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD
This study will examine the efficacy and safety of HLD200 in patients age 6-12 years with ADHD using a classroom study design.
- Trial name
- CEES (NCT02255513)
- Testing
- HLD200
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Attention Deficit Hyperactivity Disorder
Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
- Trial name
- NCT00434213
- Testing
- Daytrana
- Where
- 29 sites in United States
- Volunteers
- 309 people
- Sponsor
- Noven Therapeutics
Attention Deficit Disorder With Hyperactivity
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.
- Trial name
- Project1 (NCT00429273)
- Testing
- Guanfacine, Methylphenidate (MPH)
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- University of California, Los Angeles
Attention Deficit Hyperactivity Disorder
PK/PD Pediatric ADHD Classroom Study
The purpose of this study is to evaluate the association between blood drug levels and the corresponding scores of commonly used behavioral instruments based upon data collected following administration of three different…
- Trial name
- NCT02536105
- Testing
- Methylphenidate HCl ER tablets 1, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Disorders With Hyperactivity
Pharmacogenomics for Improving Pediatric ADHD Treatment
This research study is a randomized controlled trial (RCT) to test whether pharmacogenomics (PGx) testing for ADHD medications will help guide clinicians to choose medications and dosages for pediatric ADHD treatment that provide…
- Trial name
- NCT03730870
- Testing
- Pharmacogenomics report
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Clinical and Translational Genome Research Institute, Inc.
Attention Deficit Hyperactivity Disorder
Dasotraline Pediatric Extension Study
This is an open label 26 week extension study for subjects who completed SEP360-202.
- Trial name
- NCT02457819
- Testing
- Dasotraline
- Where
- 36 sites in United States
- Volunteers
- 237 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit-Hyperactivity Disorder
Real World Evidence of the Efficacy and Safety of FOQUEST
This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD treated with FOQUEST or VYVANSE.
- Trial name
- reFOQus (NCT04152629)
- Testing
- Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate
- Where
- 12 sites in Canada
- Volunteers
- 257 people
- Sponsor
- Purdue Pharma, Canada
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (process by which JNJ-31001074 is absorbed, distributed, metabolized, and eliminated by the body) after a single dose of JNJ-31001074.
- Trial name
- NCT00890292
- Testing
- JNJ-31001074
- Volunteers
- 18 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Hyperactivity Disorder
Comparative Effectiveness of Primary Care-based Interventions for Pediatric ADHD
Attention-deficit hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood, affecting approximately 8% of youth.
- Trial name
- NCT02105142
- Testing
- ADHD Group Visits, ADHD Group Visits plus Online Discussion Portal, Computer Decision Support
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Indiana University
Child Disruptive Behavior Disorders, Oppositional Defiant Disorder
Evaluating an Online Parenting Support System Disseminated by Pediatric Practices
This study will experimentally evaluate an internet-based version of the Triple P Positive Parenting Program, the Triple P Online System (TPOS), which presents the Triple P content in an interactive, video-enriched, and…
- Conditions
- Child Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT02064452
- Testing
- Triple P Online System
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Oregon Research Institute
Attention-deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.
- Trial name
- NCT04786730
- Testing
- Centanafadine
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Disruptive Behavior Disorders
The Parenting Young Children Check-up: Proof-of-Concept Trial
The Parenting Young Children Check-up (PYCC) is a 3-part system for parents of children with Disruptive Behavior Problems (DBPs).
- Trial name
- NCT04113304
- Testing
- Parenting Young Children Check-up (PYCC)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Wayne State University
Bipolar Disorder
Pediatric Bipolar Disorder Study at UCLA
The UCLA Semel Institute for Neuroscience in Los Angeles, CA, is conducting a study looking at similarities and differences in how the brain works between bipolar disorder and attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00961935
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, Los Angeles
Attention Deficit Hyperactivity Disorder
ERP Based Single-dose Predictions of Stimulants
The purpose of this study was to see if the clinical outcome of stimulant medication (methylphenidate) in pediatric Attention Deficit Hyperactivity Disorder can be predicted on the bases of changes in Event Related Potentials…
- Trial name
- NCT02695355
- Testing
- Methylphenidate (MPH)
- Where
- Norway
- Volunteers
- 87 people
- Sponsor
- Ostfold Hospital Trust
Pediatric ADHD
Screening Protocol for Children and Adolescents With Attention Deficit Hyperactivity Disorder
The objective of this protocol is to establish a comprehensive screening process to evaluate the eligibility of potential pediatric subjects for appropriate ADHD clinical research studies.
- Trial name
- NCT00592436
- Where
- United States
- Volunteers
- 663 people
- Sponsor
- Massachusetts General Hospital